Clinical Trials Logo

Filter by:
NCT ID: NCT02945709 Completed - PTSD Clinical Trials

Attention Control Treatment for Post Traumatic Stress Disorder ׂ(PTSD)

Start date: October 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to explore the efficacy of Attention Control Training for Post Traumatic Stress Disorder (PTSD). ACT was found to be effective in decreasing attention bias variability and PTSD symptoms in combat veterans (Badura-Brack, et al., 2015). It is now important to continue the examination of ACT's efficacy in additional populations of patients with PTSD. Such extension of treatment to other traumatic experiences raises the question of whether the threatening content of the training material could be personalized for each patient.

NCT ID: NCT02941926 Completed - Breast Cancer Clinical Trials

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

COMPLEEMENT-1
Start date: November 30, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer and no prior hormonal treatment for advanced disease..

NCT ID: NCT02941367 Completed - Clinical trials for Diabetes Mellitus, Type 2

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

LixiRam
Start date: February 23, 2017
Phase: Phase 4
Study type: Interventional

Primary Objective: To compare the safety, in terms of percentage of patients with symptomatic documented hypoglycemia during Ramadan fast, of lixisenatide versus sulfonylurea (SU). Secondary Objectives: - To assess effect of lixisenatide versus SU on: - Changes in glycemic control; - Changes in body weight. - To assess overall safety of lixisenatide and SU.

NCT ID: NCT02938624 Completed - Clinical trials for Non Small Cell Lung Carcinoma

Anti PD-1 Neo-adjuvant Treatment for NSCLC

MK3475-223
Start date: January 7, 2017
Phase: Phase 1
Study type: Interventional

A single arm, phase I, dose escalation trial and expansion cohort, examining the safety and feasibility of neoadjuvant pembrolizumab treatment for early resectable NSCLC patients. Hypothesis: The investigators hypothesize that response rate to neo-adjuvant pembrolizumab will be higher than the response rate of advanced NSCLC patients.

NCT ID: NCT02937454 Completed - Heart Failure Clinical Trials

Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency

Affirm-AHF
Start date: April 3, 2017
Phase: Phase 4
Study type: Interventional

Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency (Affirm-AHF)

NCT ID: NCT02936362 Completed - Clinical trials for Dietary Modification

Testing the Effect of Whole-wheat Sourdough Bread Compared to White Bread on Healthy Individuals

Start date: February 2016
Phase: N/A
Study type: Interventional

Bread is the most common grain product in the world, with consumption surpassing 3 billion individuals per year. Sourdough whole-grain bread is considered a healthy alternative to white, refined-wheat bread. This cross-over study will test the effect of consumption of sourdough bread compared to white bread following a short dietary intervention period (one week) on multiple clinical parameters and gut microbiota.

NCT ID: NCT02935634 Completed - Clinical trials for Advanced Gastric Cancer

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

FRACTION-GC
Start date: November 29, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

NCT ID: NCT02929953 Completed - Clinical trials for Type 1 Diabetes Mellitus

Prematurity Prevalence Among T1D Patients and Its Characteristics Compared With Premature-born Non-diabetic Patients

T1Dpremies
Start date: January 2014
Phase:
Study type: Observational

The aims of this study are: 1. To assess the prevalence of prematurity, especially early prematurity, among T1D patients, and compare it to the prematurity prevalence among the non-diabetic general population in Israel. 2. To characterize epidemiological and clinical factors that differ between premature-born patients that developed T1D and those that have not, including the nutritional and therapeutic properties in NICU.

NCT ID: NCT02928224 Completed - Clinical trials for BRAF V600E-mutant Metastatic Colorectal Cancer

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

BEACON CRC
Start date: October 13, 2016
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib + binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.

NCT ID: NCT02927314 Completed - Clinical trials for Non-alcoholic Steatohepatitis (NASH)

A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

Start date: November 27, 2017
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.